ow dose hydroxyurea in sickle cell anemia
Phase 4
Completed
- Conditions
- Health Condition 1: D649- Anemia, unspecified
- Registration Number
- CTRI/2022/01/039317
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
a)Sickle cell Anemia patients between 6-18 years of age having weight between 15-60 years either on Hydroxyurea or are started on hydroxyurea and characterized by pain episodes in the past. Painful crisis is defined as a presence of pain for 4 or more hours requiring the intervention with any injectable analgesics.
b)Patients willing to provide informed consent and assent.
Exclusion Criteria
a)Patients with other forms of sickle cell syndromes.
b)Patients on any immunosuppression drugs.
c)Patients with abnormal liver function tests.
d)Patients allergic to any drug provided during the study period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method